我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

扶正泻肝方治疗早期原发性肝癌患者疗效及对免疫功能影响*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2018年01期
页码:
34-37
栏目:
临床研究
出版日期:
2018-06-30

文章信息/Info

Title:
Clinical Research of Fuzheng Xiegan Decoction in the Treatment of Primary Hepatic Carcinoma
作者:
叶颖宋雅楠张莉君张遂亮庄菊花何赛飞夏伟
(上海中医药大学附属第七人民医院,上海 200137)
Author(s):
YE Ying SONG Yanan ZHANG Lijun ZHANG Suiliang ZHUANG Juhua HE Saifei XIA Wei
(The Seventh People’s Hospital Affiliated of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China)
关键词:
扶正泻肝方 原发性肝癌 疼痛
Keywords:
Fuzheng Xiegan decoction primary hepatic carcinoma pain
分类号:
R273
DOI:
10.19288/j.cnki.issn.1000-2723.2018.01.008
文献标识码:
A
摘要:
目的研究扶正泻肝方治疗原发性肝癌疗效及对患者免疫功能影响。方法研究对象选取40 例早期原发性肝癌患者,均给予扶正泻肝方治疗3 个月,比较治疗前后患者的肿瘤指标、肝功能指标、KPS评分、疼痛评分、免疫功能指标、中医证候积分等水平。结果治疗后,患者AFP值明显低于治疗前,AFP、ALT、AST、TBIL、DBIL均明显低于治疗前,TP水平明显高于治疗前,CD3+、CD4+ 水平及CD4+/CD8+比值均明显高于治疗前,CD8+明显低于治疗前(P<0.01),KPS评分提高率为80.0%,此外,疼痛缓解率为85.0%,各临床症状改善的有效率均大于60%. 结论扶正泻肝方治疗原发性肝癌临床疗效明显,尤其可减轻早期伴癌痛患者疼痛程度,改善患者免疫功能,促进生活质量恢复。
Abstract:
Objective To study the effect of Fuzheng Xiegan decoction on the treatment of primary liver cancer and its immune function. Methods The subjects were 40 PHC patients in our hospital from October 2016 to June 2017, were treated with Fuzheng Xiegan decoction for 3 months. Tumor index, liver function index, KPS scores, pain degree, immune function index and traditional Chinese medicine(TCM) syndrome scores were detected before and after the treatment. Results After treatment, AFP, ALT, AST, TBIL and DBIL in patients were significantly lower than those before treatment, and TP levels were significantly higher than before treatment, the levels of CD3+, CD4+ and CD4+ /CD8+ were significantly higher than those before treatment, CD8+ was significantly lower than those before treatment(P<0.01). The improvement rate of KPS score was 80.0%. In addition, the pain relief rate was 85.0%. The effective rates of all clinical symptoms were all over 60%. Conclusion Fuzheng Xiegan decoction treatment of primary liver cancer clinical significant effect, in particular, can reduce the early pain associated with cancer pain patients, improve immune function and promote the quality of life recovery.

参考文献/References

[1] CHUANG S C,LA VECCHIA C,BOFFETTA P. Liver cancer:descriptive epidemiology and risk factors other than hbv and hcv infection[J]. Cancer Letter,2009,286(1):9-14.
[2] AGOPIAN V G,KALDAS F M,HONG J C,et al. Liver transplantation for nonalcoholic steatohepatitis:the new epidemic[J]. Annals of Surgery,2012,256(4):624-633.
[3] 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 传染病信息,2017(3):111-127.
[4] 郑筱萸. 中药新药临床研究指导原则(试用)[M]. 北京:中国医药科技出版社,2002.
[5] 赵河通,翟笑枫. 中药复方治疗原发性肝癌的临床研究进展[J]. 中医药导报,2017,23(17):107-110.
[6] 郑丽宏,毛长庚. 乙肝研究与预防[J]. 中国医药导刊,2013,15(4):574-575.
[7] 高峰,韩颖盈,杨金坤. 中医药治疗原发性肝癌的临床策略[J]. 上海中医药杂志,2015,49(6):4-5.
[8] 张孟哲. 中医药治疗原发性肝癌的研究概况[J]. 中国民族民间医药,2017,26(15):76-78.
[9] 刘尧. 扶正解毒消积方对原发性肝癌2年生存率的影响和作用机制研究[D]. 北京:北京中医药大学,2015.
[10] 郜飞宇,李云芳,张爱琴. 中医药治疗原发性肝癌的临床研究进展[J]. 中国肿瘤,2011(10):764-767.
[11] 赵万爽,王颖. 中医药治疗肝癌简况[J]. 实用中医内科杂志,2017,31(9):85-87.
[12] 王文海,周荣耀,吴丽英. 补肾健脾方对原发性肝癌患者介入术后中医证候的调治作用[J]. 上海中医药大学学报,2009(3):23-25.
[13] 孙超,吴煜,陈永伦,等. 治痰三法治疗原发性肝癌的探讨——附验案3则[J]. 江苏中医药,2013(3):67-68.
[14] 曹继刚,邱幸凡,陈月雀,等. 原发性肝癌的基本病机及治则探讨[J]. 中医药学报,2008,36(4):28-29.
[15] 诸佳瑜,陈闯,欧杰,等. 中医辨证治疗原发性肝癌的研究进展[J]. 当代医药论丛,2017,15(10):32-34.
[16] 王爽,徐振晔. 徐振晔治疗肝癌经验[J]. 北京中医药,2012,31(4):282-283.
[17] 宋慧,娴乔飞,邵铭. 中医药治疗原发性肝癌的研究进展[J]. 临床肝胆病杂志,2016(1):174-177.

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金(81703791);上海市浦东新区卫生系统重点学科群建设项目(PWZxq2014-12) 收稿日期: 2018 - 01- 13 作者简介: 叶颖(1985-),女,博士,助理研究员,研究方向:中药药理。 通信作者: 夏伟,E-mail:awingxia@163. com
更新日期/Last Update: 2018-06-30